Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.90 is 259% below its 5-year average of -0.25, near the high end of its 5-year range (-65.96–12.80).
As of the fiscal period ended Tuesday, June 30, 2026. 39.63% above its 12-month average of -1.49.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.90.
DEBT TO EQUITY RATIO
-0.90
DEBT TO EQUITY RATIO AVG TTM
-1.49
DEBT TO EQUITY RATIO AVG 3Y
-1.29
DEBT TO EQUITY RATIO AVG 5Y
-0.25
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+39.63%
CURRENT VS 3Y AVG
+30.09%
CURRENT VS 5Y AVG
-258.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
-919.82%
vs the sector median at left
Market Cap
$50.51M
Debt to Equity Ratio
0.00
TTM Avg
0.89
3Y Avg
0.55
5Y Avg
0.44
Market Cap
$50.96M
Debt to Equity Ratio
0.25
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$51.05M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.15
5Y Avg
0.12
Market Cap
$49.55M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$49.22M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $50.67M | -0.90 | -1.49 | -1.29 | -0.25 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.51M | 0.00 | 0.89 | 0.55 | 0.44 |
| Envoy Medical, Inc. (COCH)vs › | $50.96M | 0.25 | 0.00 | 0.00 | 0.00 |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.05M | 0.00 | 0.00 | 0.15 | 0.12 |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | 0.30 | 0.25 | 0.31 | 0.39 |
| Apollomics, Inc. (APLM)vs › | $49.72M | N/A | 0.15 | 0.15 | 0.15 |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.55M | 0.01 | 0.01 | 0.02 | 0.02 |
| INmune Bio, Inc. (INMB)vs › | $49.45M | 0.07 | 0.03 | 0.14 | 0.13 |
| Microbot Medical Inc. (MBOT)vs › | $49.22M | 0.01 | 0.02 | 0.04 | 0.04 |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | 5.17 | 3.87 | 2.95 |
Debt/Equity
-0.90
Current Ratio
3.07
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.90 |
| 2026-03-31 | -1.17 |
| 2025-12-31 | -1.23 |
| 2025-09-30 | -1.72 |
| 2025-06-30 | -2.44 |
| 2025-03-31 | -4.21 |
| 2024-12-31 | -2.35 |
| 2024-09-30 | -5.55 |
| 2024-06-30 | -65.96 |
| 2024-03-31 | 7.61 |
| 2023-12-31 | 2.40 |
| 2023-09-30 | 1.52 |
| 2023-06-30 | 1.47 |
| 2023-03-31 | -19.89 |
| 2022-12-31 | 9.83 |
| 2022-09-30 | -2.88 |
| 2022-06-30 | -47.49 |
| 2022-03-31 | 12.80 |
| 2021-12-31 | 1.91 |
| 2021-09-30 | 4.18 |
| 2021-06-30 | -0.65 |
| 2021-03-31 | -0.11 |
| 2020-12-31 | 12.68 |
| 2020-09-30 | 0.11 |
| 2020-06-30 | 6.78 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.36 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
